BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25678374)

  • 1. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    Hoffman RM; Koyama T; Albertsen PC; Barry MJ; Daskivich TJ; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Potosky AL; Penson DF
    J Gen Intern Med; 2015 Jul; 30(7):924-34. PubMed ID: 25678374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
    Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
    Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
    Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
    Abdollah F; Sun M; Schmitges J; Tian Z; Jeldres C; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Eur Urol; 2011 Nov; 60(5):920-30. PubMed ID: 21741762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
    Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
    Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
    D'Amico AV; Renshaw AA; Sussman B; Chen MH
    JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
    Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical management and burden of prostate cancer: a Markov Monte Carlo model.
    Sanyal C; Aprikian A; Cury F; Chevalier S; Dragomir A
    PLoS One; 2014; 9(12):e113432. PubMed ID: 25474006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool.
    Frendl DM; FitzGerald G; Epstein MM; Allison JJ; Sokoloff MH; Ware JE
    PLoS One; 2020; 15(12):e0240039. PubMed ID: 33284845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
    Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
    Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
    Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
    Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
    J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
    Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
    J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical Activity and Survival After Prostate Cancer.
    Friedenreich CM; Wang Q; Neilson HK; Kopciuk KA; McGregor SE; Courneya KS
    Eur Urol; 2016 Oct; 70(4):576-585. PubMed ID: 26774959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer outcomes for men who present with symptoms at diagnosis.
    Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
    BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation.
    Sun M; Sammon JD; Becker A; Roghmann F; Tian Z; Kim SP; Larouche A; Abdollah F; Hu JC; Karakiewicz PI; Trinh QD
    BJU Int; 2014 Feb; 113(2):200-8. PubMed ID: 23937636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
    Aizer AA; Chen MH; Hattangadi J; D'Amico AV
    BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.